Acute Myeloid Leukemia (AML) - Drug Pipeline Landscape, 2023

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,000	643 Pages	Global Insight Services	January, 2023	GIS17645081

Best Price Guarantee
Price	from $2,000
Length	643 Pages
Publisher	Global Insight Services
Published Date	January, 2023
SKU	GIS17645081

Acute Myeloid Leukemia (AML) - Drug Pipeline Landscape, 2023

Leukemia is a malignant disease of the blood cells. The four main types of leukemia are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). AML is the most common type of leukemia in adults, accounting for about 80% of all cases.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) is a type of blood cancer in which the bone marrow produces a large number of abnormal blood cells which is also called as Acute Myeloid Leukemia, Acute Granulocytic Leukemia and Acute Nonlymphocytic Leukemia.

The most common causes of Acute Myelocytic Leukemia are mutations in the DNA, smoking, previous chemotherapy treatment, exposure to radiation, hazardous chemical exposure, age, other genetic or blood disorders.

The most common symptoms of Acute Myelocytic Leukemia include fever, fatigue, paleness or loss of normal skin colour, unusual bleeding/ bruises, frequent infections, headache, weight loss, shortness of breath etc.

Acute Myelocytic Leukemia can be diagnosed by the doctors by a physical exam to look for signs of bleeding, bruising, or infection. Diagnostic tests include Blood tests, Imaging tests, Bone marrow tests, Spinal tap, Genetic tests etc.

The most common treatments for Acute Myelocytic Leukemia are Chemotherapy, Radiotherapy, Stem cell transplantation, Targeted therapy with either or combinations as Remission induction therapy and Consolidation therapy.

The prognosis for AML varies depending on the age of the patient and the subtype of the disease. In general, the outlook is better for younger patients and those with certain subtypes of AML. With treatment, many people are able to achieve remission, but the disease can recur.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Acute Myeloid Leukemia (AML) treatment such as ASTX727, Omidubicel, Quizartinib, Magrolimab, Uproleselan and others. Key players involved in the development of therapies to treat acute myeloid leukemia are Astex Pharmaceuticals Inc, Gamida Cell, Daiichi Sankyo Co Ltd, Gilead Sciences, GlycoMimetics Incorporated and others. Three drugs are under late-stage Pre-Registration, thirteen drugs are under Phase III clinical trials, ninety drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages of development.

In December 2022, Gamida Cell presented Omidubicel data at the 64th American Society of Hematology (ASH) annual meeting.

In December 2022, GlycoMimetics presented new Uproleselan clinical data in both frontline unfit and treated secondary acute myeloid leukemia at the American Society of Hematology (ASH) annual meeting.

Report Highlights

Global Insight Service's, Acute Myeloid Leukemia (AML) - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Myeloid Leukemia (AML) pipeline drugs. This report covers detailed insights on Acute Myeloid Leukemia (AML) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Myeloid Leukemia (AML) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction: 1.1 Acute Myeloid Leukemia (AML) – Pipeline Drugs, 2023 - Coverage
2. Disease Overview – Acute Myeloid Leukemia (AML): 2.1 Causes; 2.2 Signs and Symptoms; 2.3 Diagnosis; 2.4 Disease Management
3. Acute Myeloid Leukemia (AML) – Pipeline Drugs Development - Overview: 3.1 Comparative Analysis by Stage of Development; 3.2 Number of Products under Development by Companies, 2023; 3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics: 4.1 Assessment by Target; 4.2 Assessment by Mechanism of Action; 4.3 Assessment by Molecule Type; 4.3 Assessment by Route of Administration
5. Drug Profiles: 5.1 Late Stage Drugs – Pre-Registration; 5.1.1. ASTX727; 5.1.2. Omidubicel; 5.1.3. Quizartinib; 5.2 Clinical Stage Drugs – Phase III; 5.2.1 ASTX030; 5.2.2 Crenolanib; 5.2.3 DFP-10917; 5.2.4 Galinpepimut-S; 5.2.5 Gilteritinib; 5.2.6 JZP351; 5.2.7 Magrolimab; 5.2.8 OmnImmune; 5.2.9 Orca-T; 5.2.10 SKLB1028; 5.2.11 Uproleselan; 5.2.12 Vosaroxin; 5.3 Clinical Stage Drugs – Phase II; 5.3.1 AB8939; 5.3.2 AK117; 5.3.3 Alrizomadlin; 5.3.4 Antroquinonol; 5.3.5 APR-246; 5.3.6 ASP7517; 5.3.7 Aspacytarabine; 5.3.8 Bemcentinib; 5.3.9 Bexmarilimab; 5.3.10 BGB-11417; 5.3.11 BI 836858; 5.3.12 Bisantrene; 5.3.13 Camidanlumab Tesirine; 5.3.14 CART-19 T Cell; 5.3.15 CCS1477; 5.3.16 CD123 CAR-T Cells; 5.3.17 CFI-400945; 5.3.18 CGT9486; 5.3.19 Cusatuzumab; 5.3.20 CWP232291; 5.3.21 Cytokine Induced Memory-like NK Cells; 5.3.22 DCP-001; 5.3.23 Dendritic Cell/AML Fusion Cell Vaccine; 5.3.24 Dendritic Cell/AML Vaccine; 5.3.25 Dilanubicel; 5.3.26 DSP-5336; 5.3.27 Dubermatinib; 5.3.28 E7820; 5.3.29 Eltanexor; 5.3.30 Emavusertib; 5.3.31 Enasidenib; 5.3.32 EP0042; 5.3.33 Evorpacept; 5.3.34 FF-10101-01; 5.3.35 Ficlatuzumab; 5.3.36 Flotetuzumab; 5.3.37 FLYSYN; 5.3.38 Fosciclopirox; 5.3.39 GTA002; 5.3.40 HM43239; 5.3.41 Humanized CD7 CAR-T Cells; 5.3.42 HYML-122; 5.3.43 Iadademstat; 5.3.44 Ibrutinib; 5.3.45 IMM01; 5.3.46 Isatuximab; 5.3.47 Lanraplenib; 5.3.48 LAVA-051; 5.3.49 Lemzoparlimab; 5.3.50 Lenalidomide; 5.3.51 Lintuzumab-Ac225; 5.3.52 Liposomal Annamycin; 5.3.53 Lisaftoclax; 5.3.54 Max-40279; 5.3.55 MDG1011; 5.3.56 Midostaurin (Pediatrics); 5.3.57 Mitoxantrone Liposome; 5.3.58 Mocravimod; 5.3.59 Motixafortide; 5.3.60 MT-401; 5.3.61 Navtemadlin; 5.3.62 NEXI-001 T Cells; 5.3.63 Nivolumab; 5.3.64 NKR-2 Cells; 5.3.65 NMS-03592088; 5.3.66 ONC201; 5.3.67 ONO-7475; 5.3.68 Onvansertib; 5.3.69 Orca-Q; 5.3.70 OXi4503; 5.3.71 Pembrolizumab; 5.3.72 Pivekimab Sunirine; 5.3.73 Ponatinib; 5.3.74 Prexigebersen; 5.3.75 Revumenib; 5.3.76 S64315; 5.3.77 S65487; 5.3.78 Sabatolimab; 5.3.79 SAR443579; 5.3.80 SEL24/MEN1703; 5.3.81 Siremadlin; 5.3.82 Sorafenib; 5.3.83 TAA05; 5.3.84 Talazoparib; 5.3.85 Tamibarotene; 5.3.86 TL-895; 5.3.87 TTI-622; 5.3.88 VOR33; 5.3.89 WU-NK-101; 5.3.90 Ziftomenib; 5.4 Clinical Stage Drugs – Phase I; 5.4.1 ABBV-621; 5.4.2 ABD-3001; 5.4.3 ADI-PEG 20; 5.4.4 AMG 176; 5.4.5 AMG 427; 5.4.6 Anti-CD33 CAR NK Cells; 5.4.7 APVO436; 5.4.8 Autologous CAR-T Cells; 5.4.9 AZD4573; 5.4.10 BG-1805; 5.4.11 BMF-219; 5.4.12 BN301; 5.4.13 Bomedemstat; 5.4.14 BP1002; 5.4.15 BTX-1188; 5.4.16 BTX-A51; 5.4.17 CB-5339; 5.4.18 CC-90009; 5.4.19 CC-90011; 5.4.20 CC-91633; 5.4.21 CC-95251; 5.4.22 CC-96191; 5.4.23 CD33xCD3 Bispecific Antibody; 5.4.24 Chidamide; 5.4.25 Clifutinib Besylate; 5.4.26 CLN-049; 5.4.27 CYAD-02; 5.4.28 CYNK-001; 5.4.29 DARIC33 (Pediatric); 5.4.30 Donafenib; 5.4.31 Double Negative T Cells; 5.4.32 DS-1594; 5.4.33 DSP107; 5.4.34 Entrectinib; 5.4.35 F16IL2; 5.4.36 Fadraciclib; 5.4.37 FT516; 5.4.38 FT538; 5.4.39 Gentulizumab; 5.4.40 GNC-035; 5.4.41 GSK3745417; 5.4.42 HMPL-306; 5.4.43 IGM-8444; 5.4.44 Imetelstat; 5.4.45 INB-100; 5.4.46 IO-202; 5.4.47 JEZ567; 5.4.48 JNJ-63709178; 5.4.49 JNJ-67571244; 5.4.50 JNJ-74856665; 5.4.51 KITE-222; 5.4.52 KPT-9274; 5.4.53 LNK01002; 5.4.54 LP-108; 5.4.55 LP-118; 5.4.56 Luxeptinib; 5.4.57 LY3214996; 5.4.58 LY3410738; 5.4.59 Mana 312; 5.4.60 MB-102; 5.4.61 MCLA-117; 5.4.62 MGTA-117; 5.4.63 Minnelide; 5.4.64 MK-0482; 5.4.65 MRX-2843; 5.4.66 Navitoclax; 5.4.67 NEI-01; 5.4.68 Nintedanib; 5.4.69 NKX101; 5.4.70 NTX 301; 5.4.71 OPB-111077; 5.4.72 PDR001; 5.4.73 Pemigatinib; 5.4.74 PHI-101; 5.4.75 PLX2853; 5.4.76 PRGN-3006; 5.4.77 PRT1419; 5.4.78 PRT543; 5.4.79 Pyronaridine Tetraphosphate; 5.4.80 RC1012; 5.4.81 Regorafenib; 5.4.82 RO7283420; 5.4.83 RVT-2001; 5.4.84 RVU120; 5.4.85 SAR445419; 5.4.86 SEA-CD70; 5.4.87 Selinexor; 5.4.88 SH1573; 5.4.89 SHR-1702; 5.4.90 SKI-G-801; 5.4.91 SL-172154 + Azacitidine +/- Venetoclax; 5.4.92 SL-401; 5.4.93 SY-2101; 5.4.94 TAS1440; 5.4.95 TAS1553; 5.4.96 Tegavivint; 5.4.97 TQB2618; 5.4.98 UCART123; 5.4.99 UniCAR02-T-CD123; 5.4.100 Voruciclib; 5.4.101 XmAb14045; 5.4.102 XY0206; 5.4.103 Zilovertamab Vedotin; 5.4.104 ZN-d5; 5.5 Early Stage Drugs – Phase 0; 5.5.1 Anti-CD33/CLL1 Conjugated Antibody Redirecting Natural Killer Cells; 5.5.2 Anti-ILT3 CAR-T Cells; 5.5.3 CD70 CAR T-cells; 5.5.4 CLL1-CD33 cCAR T Cells; 5.5.5 Interferon Gamma-1b; 5.6 Early Stage Drugs – IND/CTA Filed; 5.6.1 ICP-248; 5.6.2 NC 525; 5.6.3 TBX-2400; 5.7 Early Stage Drugs – Preclinical; 5.7.1 6MW3211; 5.7.2 AB 001; 5.7.3 ABL 602; 5.7.4 ACLX-002; 5.7.5 ACLX-003; 5.7.6 AFM28; 5.7.7 AFM28 + Adoptive Natural Killer Cells; 5.7.8 ALLO-316; 5.7.9 ALLO-819; 5.7.10 AMG 553; 5.7.11 Angiocidin; 5.7.12 Anti-CD33 CAR-T Cells; 5.7.13 AST-081; 5.7.14 BIO-107; 5.7.15 BMF-500; 5.7.16 BN104; 5.7.17 BS HH 002.SA; 5.7.18 BXCL701; 5.7.19 CDX Bi-specific Antibodies; 5.7.20 Ceramide NanoLiposome; 5.7.21 Cresorol; 5.7.22 CXCR4-ADRB2 Inhibitor; 5.7.23 CYC140; 5.7.24 CYTO NK-201; 5.7.25 DARIC33 Next-Gen (Adults); 5.7.26 DIACC2010; 5.7.27 Dual IRAK1/4 and PanFLT3 Inhibitors; 5.7.28 ELU001; 5.7.29 ETN003; 5.7.30 Fb-PMT; 5.7.31 FLT3-targeting TriTACs; 5.7.32 GC017; 5.7.33 GFH009; 5.7.34 GMI-1359; 5.7.35 GMI-1687; 5.7.36 GTB-3650; 5.7.37 HBI ONC; 5.7.38 HFB 200902; 5.7.39 HP 537; 5.7.40 HY007; 5.7.41 IGM 2537; 5.7.42 IL3 CAR T-cells; 5.7.43 IM73 CAR-T Cells; 5.7.44 JBI-802; 5.7.45 KVX 053; 5.7.46 MANA-412; 5.7.47 MB-dNPM1-TCR.1; 5.7.48 MBK-101; 5.7.49 ME 344; 5.7.50 Melflufen; 5.7.51 METTL3-inhibitor; 5.7.52 MP0533; 5.7.53 NKG2D CAR-T Cells; 5.7.54 NTLA-5001; 5.7.55 NUC 7738; 5.7.56 Olverembatinib; 5.7.57 ORM-6151; 5.7.58 OXB-302; 5.7.59 P-ckit-ALLO1; 5.7.60 PDS0102; 5.7.61 PHI-501; 5.7.62 PLD-102; 5.7.63 QN 247; 5.7.64 RD127; 5.7.65 RD137; 5.7.66 RMC 4550; 5.7.67 RRx-001; 5.7.68 SENTI-202; 5.7.69 SGR-2921; 5.7.70 SNDX 50469; 5.7.71 STC-15; 5.7.72 STM2457; 5.7.73 SYHX1903; 5.7.74 TACSYN; 5.7.75 TCX-101; 5.7.76 TP-0184; 5.7.77 UCAR-gamma Delta T Cells; 5.7.78 VCAR33 (Allogeneic); 5.7.79 VCAR33 (Autologous); 5.7.80 VIP943; 5.7.81 VOR33 + VCAR33; 5.7.82 WU-CART-007; 5.8 Early Stage Drugs – Discovery; 5.8.1 BG-1905; 5.8.2 CB-012; 5.8.3 CNTY-104; 5.8.4 DUET-03; 5.8.5 EPC-005; 5.8.6 EV101; 5.8.7 FabG1-2139; 5.8.8 SH-114; 5.8.9 TATX-22; 5.8.10 UBG-T/NK/γδ T; 5.8.11 UCAR-NK; 5.8.12 Undisclosed; 5.8.13 Undisclosed; 5.8.14 Undisclosed; 5.8.15 VOR33-CLL1 + VCAR33-CLL1; 5.9 Unknown Stage Drugs; 5.9.1 STRO-002
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved: 9.1 2seventy bio; 9.2 AB Science; 9.3 AbbVie; 9.4 ABL Bio; 9.5 Actinium Pharmaceuticals; 9.6 ADC Therapeutics S.A.; 9.7 Advanced BioDesign; 9.8 Affimed N.V.; 9.9 Agastiya Biotech; 9.10 Akeso; 9.11 Allogene Therapeutics; 9.12 ALX Oncology Inc.; 9.13 Amgen; 9.14 Aprea Therapeutics; 9.15 Aptevo Therapeutics; 9.16 Aptose Biosciences Inc.; 9.17 Arcellx, Inc.; 9.18 Argenx; 9.19 Armaceutica, Inc; 9.20 Arog Pharmaceuticals, Inc.; 9.21 Ascentage Pharma Group Inc; 9.22 Astellas Pharma Inc; 9.23 Astex Pharmaceuticals, Inc.; 9.24 Aston Sci. Inc.; 9.25 AstraZeneca; 9.26 AvenCell Europe GmbH; 9.27 AVEO Pharmaceuticals, Inc; 9.28 Bayer; 9.29 BeiGene; 9.30 Beijing Immunochina Medical Science & Technology Co., Ltd.; 9.31 BerGenBio ASA; 9.32 BioLineRx, Ltd.; 9.33 Biomea Fusion; 9.34 BiOneCure Therapeutics; 9.35 BioNova Pharmaceuticals; 9.36 Bio-Path Holdings, Inc.; 9.37 BioSight Ltd.; 9.38 BioTheryX, Inc.; 9.39 BioXcel Therapeutics; 9.40 BlueSphere Bio; 9.41 Boehringer Ingelheim; 9.42 Bristol-Myers Squibb; 9.43 Carbiogene Therapeutics Co. Ltd; 9.44 Cardiff Oncology; 9.45 Caribou Biosciences; 9.46 CellCentric Ltd.; 9.47 Cellectis S.A.; 9.48 Cellestia; 9.49 Celularity Incorporated; 9.50 Celyad Oncology SA; 9.51 Century Therapeutics; 9.52 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; 9.53 Chimerix; 9.54 Chipscreen Biosciences, Ltd.; 9.55 Chongqing Precision Biotech Co., Ltd; 9.56 CicloMed LLC; 9.57 Cleave Therapeutics, Inc.; 9.58 Cogent Biosciences, Inc.; 9.59 CSPC Ouyi Pharmaceutical Co Ltd; 9.60 CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; 9.61 Cullinan Oncology, LLC; 9.62 Curis, Inc.; 9.63 Cyclacel Pharmaceuticals, Inc; 9.64 CytoImmune Therapeutics; 9.65 Daiichi Sankyo Inc; 9.66 Delta-Fly Pharma, Inc.; 9.67 Denovo Biopharma; 9.68 DIACCURATE; 9.69 Duet BioTherapeutics; 9.70 Eisai Inc.; 9.71 Eli Lilly and Company; 9.72 Ellipses Pharma; 9.73 Elpis Biopharmaceuticals; 9.74 Elucida Oncology; 9.75 EpicentRx, Inc; 9.76 EvolveImmune Therapeutics; 9.77 Faron Pharmaceuticals Ltd; 9.78 Fate Therapeutics; 9.79 FatiAbGen; 9.80 Flavocure Biotech; 9.81 Fujifilm Pharmaceuticals U.S.A., Inc.; 9.82 Gamida Cell ltd; 9.83 Genentech, Inc.; 9.84 GeneScience Pharmaceuticals Co., Ltd; 9.85 Geron Corporation; 9.86 Gilead Sciences; 9.87 GlaxoSmithKline; 9.88 GlycoMimetics Incorporated; 9.89 Glycostem Therapeutics BV; 9.90 Golden Biotechnology Corporation; 9.91 GPCR Therapeutics; 9.92 Gracell Biotechnologies Inc; 9.93 GT Biopharma, Inc.; 9.94 Guangdong Ruishun Biotech Co., Ltd; 9.95 Guangzhou Bio-Gene Technology Co., Ltd; 9.96 Harpoon Therapeutics; 9.97 Hemavant Sciences GmbH; 9.98 Hemogenyx Pharmaceuticals plc; 9.99 HiFiBiO; 9.100 Hinova pharmaceuticals; 9.101 Hoffmann-La Roche; 9.102 Horizon Pharma USA, Inc.; 9.103 Hutchison Medipharma Limited; 9.104 HUYA Bioscience International; 9.105 iCell Gene Therapeutics; 9.106 IGM Biosciences; 9.107 I-Mab Biopharma Co. Ltd.; 9.108 Imago BioSciences,Inc.; 9.109 Imbioray (Hangzhou) Biomedicine Co., Ltd.; 9.110 Immune-Onc Therapeutics; 9.111 ImmuneOnco; 9.112 ImmunityBio, Inc.; 9.113 ImmunoGen, Inc.; 9.114 In8bio Inc.; 9.115 Incyte Corporation; 9.116 InnoCare Pharma; 9.117 Intellia Therapeutics; 9.118 Ipsen; 9.119 Iterion Therapeutics; 9.120 Janssen Research & Development, LLC; 9.121 Jazz Pharmaceuticals; 9.122 Jiangsu HengRui Medicine Co., Ltd.; 9.123 Jubilant Therapeutics; 9.124 Juventas; 9.125 JW Pharmaceutical; 9.126 Kahr Medical; 9.127 Kartos Therapeutics, Inc.; 9.128 Karyopharm Therapeutics Inc; 9.129 KeViRx; 9.130 Keystone Nano, Inc; 9.131 Kite Pharma; 9.132 Kronos Bio; 9.133 Kura Oncology, Inc.; 9.134 Kurome Therapeutics; 9.135 Lava Therapeutics; 9.136 Loxo Oncology, Inc.; 9.137 Lynk Pharmaceuticals Co., Ltd; 9.138 Mablink Bioscience; 9.139 Mabwell (Shanghai) Bioscience Co., Ltd.; 9.140 MacroGenics; 9.141 Magenta Therapeutics, Inc.; 9.142 Mana Therapeutics; 9.143 Marker Therapeutics, Inc.; 9.144 Maxinovel Pty., Ltd.; 9.145 Medigene AG; 9.146 Medivation, Inc; 9.147 MEI Pharma, Inc.; 9.148 Menarini Group; 9.149 Mendus; 9.150 Merck Sharp & Dohme LLC; 9.151 Merus N.V.; 9.152 Miltenyi Biomedicine; 9.153 Minneamrita Therapeutics LLC; 9.154 Molecular Partners; 9.155 Moleculin Biotech, Inc.; 9.156 Mustang Bio, Inc.; 9.157 Nanjing Iaso Biotherapeutics Co. Ltd; 9.158 Nanjing Sanhome Pharmaceutical, Co., Ltd.; 9.159 NanoPharmaceuticals; 9.160 Nerviano Medical Sciences; 9.161 New Epsilon Innovation Limited; 9.162 Newave Pharmaceutical Inc; 9.163 NexImmune Inc.; 9.164 NextCure; 9.165 Nkarta Inc.; 9.166 Nohla Therapeutics, Inc.; 9.167 Novartis; 9.168 NuCana; 9.169 Oncopeptides; 9.170 Oncotelic Therapeutics; 9.171 Ono Pharmaceutical; 9.172 Orca Biosystems, Inc.; 9.173 Orum Therapeutics; 9.174 Oryzon Genomics S. A.; 9.175 Oscotec Inc.; 9.176 Otsuka America Pharmaceutical; 9.177 Oxford BioMedica; 9.178 PDS Biotechnology Corporation; 9.179 PeLeMed; 9.180 PersonGen Biotherapeutics; 9.181 Pfizer; 9.182 Pharmacyclics LLC.; 9.183 Pharos iBio Co., Ltd.; 9.184 Philogen S.p.A.; 9.185 Pinotbio; 9.186 Polaris Group; 9.187 Poseida Therapeutics; 9.188 Precigen, Inc; 9.189 Prelude Therapeutics; 9.190 Priothera SAS; 9.191 Protheragen; 9.192 Qualigen Therapeutics; 9.193 Race Oncology Ltd; 9.194 Revolution Medicines; 9.195 Ryvu Therapeutics SA; 9.196 Sanofi; 9.197 Schrodinger; 9.198 Seagen Inc.; 9.199 Sellas Life Sciences Group; 9.200 Senti Biosciences; 9.201 Servier; 9.202 Shanghai Bensen Pharmaceutical Co., Ltd.; 9.203 Shanghai ETERN Biopharma; 9.204 Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; 9.205 Shattuck Labs, Inc.; 9.206 Shijiazhuang Yiling Pharmaceutical Co. Ltd; 9.207 Shorla Oncology; 9.208 Sichuan Baili Pharmaceutical Co., Ltd; 9.209 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.; 9.210 Stemline Therapeutics, Inc.; 9.211 Storm Therapeutics Ltd; 9.212 Sumitomo Pharma Oncology; 9.213 Sunshine Lake Pharma Co., Ltd.; 9.214 Sutro Biopharma; 9.215 Suzhou Zelgen Biopharmaceuticals Co.,Ltd; 9.216 Syndax Pharmaceuticals; 9.217 Synimmune GmbH; 9.218 Syros Pharmaceuticals; 9.219 Taiga Biotechnologies, Inc.; 9.220 Talem Therapeutics; 9.221 Tarapeutics Science Inc.; 9.222 TC Biopharm; 9.223 Telios Pharma, Inc.; 9.224 Treadwell Therapeutics, Inc; 9.225 UTC Therapeutics Inc.; 9.226 VelosBio Inc.; 9.227 Vincerx Pharma; 9.228 Vor Biopharma; 9.229 Wugen, Inc.; 9.230 Xcovery Holdings, Inc; 9.231 Xencor, Inc; 9.232 Yake Biotechnology Ltd.; 9.233 Y-mAbs Therapeutics; 9.234 Zentalis Pharmaceuticals
10. Dormant Drugs: 10.1 Inactive Drugs; 10.2 Discontinued Drugs
11. Appendix: List of Tables; Table 1.1 Number of Products under Development by Acute Myeloid Leukemia (AML); Table 1.2 Number of Products under Development by Companies; Table 1.3 Products under Development by Companies; Table 1.4 Products by Targets; Table 1.5 Products by Mechanism of Action; Table 1.6 Products by Molecule Type; Table 1.7 Products by Route of Administration; Table 2.1 Clinical Trial Details - ASTX030/Astex Pharmaceuticals, Inc.; Table 2.2 Clinical Trial Details - Crenolanib/Arog Pharmaceuticals, Inc.; Table 2.3 Clinical Trial Details - DFP-10917/Delta-Fly Pharma, Inc.; Table 2.4 Clinical Trial Details - Galinpepimut-S/Sellas Life Sciences Group; Table 2.5 Clinical Trial Details - Gilteritinib/Astellas Pharma Inc; Table 2.6 Clinical Trial Details - JZP351/Jazz Pharmaceuticals; Table 2.7 Clinical Trial Details - Magrolimab/Gilead Sciences; Table 2.8 Clinical Trial Details - OmnImmune/TC Biopharm; Table 2.9 Clinical Trial Details - Orca-T/Orca Biosystems, Inc.; Table 2.10 Clinical Trial Details - SKLB1028/CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Table 2.11 Clinical Trial Details - Uproleselan/GlycoMimetics Incorporated; Table 2.12 Clinical Trial Details - Vosaroxin/Denovo Biopharma; Table 2.13 Clinical Trial Details - AB8939/AB Science; Table 2.14 Clinical Trial Details - AK117/Akeso; Table 2.15 Clinical Trial Details - Alrizomadlin/Ascentage Pharma Group Inc.; Table 2.16 Clinical Trial Details - Antroquinonol/Golden Biotechnology Corporation; Table 2.17 Clinical Trial Details - APR-246/Aprea Therapeutics; Table 2.18 Clinical Trial Details - ASP7517/Astellas Pharma Inc; Table 2.19 Clinical Trial Details - Aspacytarabine/BioSight Ltd.; Table 2.20 Clinical Trial Details - Bemcentinib/BerGenBio ASA; Table 2.21 Clinical Trial Details - Bexmarilimab/Faron Pharmaceuticals Ltd; Table 2.22 Clinical Trial Details - BGB-11417/BeiGene; Table 2.23 Clinical Trial Details - BI 836858/Boehringer Ingelheim; Table 2.24 Clinical Trial Details - Bisantrene/Race Oncology Ltd; Table 2.25 Clinical Trial Details - Camidanlumab Tesirine/ADC Therapeutics S.A.; Table 2.26 Clinical Trial Details - CART-19 T Cell/Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Table 2.27 Clinical Trial Details - CCS1477/CellCentric Ltd.; Table 2.28 Clinical Trial Details - CD123 CAR-T cells/Chongqing Precision Biotech Co., Ltd; Table 2.29 Clinical Trial Details - CFI-400945/Treadwell Therapeutics, Inc; Table 2.30 Clinical Trial Details - CGT9486/Cogent Biosciences, Inc.; Table 2.31 Clinical Trial Details - Cusatuzumab/Argenx; Table 2.32 Clinical Trial Details - CWP232291/JW Pharmaceutical; Table 2.33 Clinical Trial Details - Cytokine Induced Memory-like NK Cells/ImmunityBio, Inc.; Table 2.34 Clinical Trial Details - DCP-001/Mendus; Table 2.35 Clinical Trial Details - Dendritic Cell/AML Fusion Cell Vaccine/Bristol-Myers Squibb; Table 2.36 Clinical Trial Details - Dendritic Cell/AML Vaccine/Medivation, Inc; Table 2.37 Clinical Trial Details - Dilanubicel/Nohla Therapeutics, Inc.; Table 2.38 Clinical Trial Details - DSP-5336/Sumitomo Pharma Oncology, Inc.; Table 2.39 Clinical Trial Details - Dubermatinib /Sumitomo Pharma Oncology, Inc.; Table 2.40 Clinical Trial Details - E7820/Eisai Inc.; Table 2.41 Clinical Trial Details - Eltanexor/Karyopharm Therapeutics Inc; Table 2.42 Clinical Trial Details - Emavusertib/Curis, Inc.; Table 2.43 Clinical Trial Details - Enasidenib/Bristol-Myers Squibb; Table 2.44 Clinical Trial Details - EP0042/Ellipses Pharma; Table 2.45 Clinical Trial Details - Evorpacept/ALX Oncology Inc.; Table 2.46 Clinical Trial Details - FF-10101-01/Fujifilm Pharmaceuticals U.S.A., Inc.; Table 2.47 Clinical Trial Details - Ficlatuzumab/AVEO Pharmaceuticals, Inc; Table 2.48 Clinical Trial Details - Flotetuzumab/MacroGenics; Table 2.49 Clinical Trial Details - FLYSYN/Synimmune GmbH; Table 2.50 Clinical Trial Details - Fosciclopirox/CicloMed LLC; Table 2.51 Clinical Trial Details - GTA002/Glycostem Therapeutics BV; Table 2.52 Clinical Trial Details - HM43239/Aptose Biosciences Inc.; Table 2.53 Clinical Trial Details - Humanized CD7 CAR-T cells/PersonGen BioTherapeutics (Suzhou) Co., Ltd.; Table 2.54 Clinical Trial Details - HYML-122/Tarapeutics Science Inc.; Table 2.55 Clinical Trial Details - Iadademstat/Oryzon Genomics S. A.; Table 2.56 Clinical Trial Details - Ibrutinib/Pharmacyclics LLC.; Table 2.57 Clinical Trial Details - IMM01/ImmuneOnco; Table 2.58 Clinical Trial Details - Isatuximab/Sanofi; Table 2.59 Clinical Trial Details - Lanraplenib/Kronos Bio; Table 2.60 Clinical Trial Details - LAVA-051/Lava Therapeutics; Table 2.61 Clinical Trial Details - Lemzoparlimab/I-Mab Biopharma Co. Ltd.; Table 2.62 Clinical Trial Details - Lenalidomide/Bristol-Myers Squibb; Table 2.63 Clinical Trial Details - Lintuzumab-Ac225/Actinium Pharmaceuticals; Table 2.64 Clinical Trial Details - Liposomal Annamycin/Moleculin Biotech, Inc.; Table 2.65 Clinical Trial Details - Lisaftoclax/Ascentage Pharma Group Inc; Table 2.66 Clinical Trial Details - Max-40279/Maxinovel Pty., Ltd.; Table 2.67 Clinical Trial Details - MDG1011/Medigene AG; Table 2.68 Clinical Trial Details - Midostaurin (Pediatrics)/Novartis; Table 2.69 Clinical Trial Details - Mitoxantrone Liposome/CSPC Ouyi Pharmaceutical Co., Ltd; Table 2.70 Clinical Trial Details - Mocravimod/Priothera SAS; Table 2.71 Clinical Trial Details - Motixafortide/BioLineRx, Ltd.; Table 2.72 Clinical Trial Details - MT-401/Marker Therapeutics, Inc.; Table 2.73 Clinical Trial Details - Navtemadlin/Kartos Therapeutics, Inc.; Table 2.74 Clinical Trial Details - NEXI-001 T Cells/NexImmune Inc.; Table 2.75 Clinical Trial Details - Nivolumab/Bristol-Myers Squibb; Table 2.76 Clinical Trial Details - NKR-2 Cells/Celyad Oncology SA; Table 2.77 Clinical Trial Details - NMS-03592088/Nerviano Medical Sciences; Table 2.78 Clinical Trial Details - ONC201/Chimerix; Table 2.79 Clinical Trial Details - ONO-7475/Ono Pharmaceutical; Table 2.80 Clinical Trial Details - Onvansertib/Cardiff Oncology; Table 2.81 Clinical Trial Details - Orca-Q/Orca Biosystems, Inc.; Table 2.82 Clinical Trial Details - OXi4503/Oncotelic Therapeutics; Table 2.83 Clinical Trial Details - Pembrolizumab/Merck Sharp & Dohme LLC; Table 2.84 Clinical Trial Details - Pivekimab Sunirine/ImmunoGen, Inc.; Table 2.85 Clinical Trial Details - Ponatinib/Incyte Corporation; Table 2.86 Clinical Trial Details - Prexigebersen/Bio-Path Holdings, Inc.; Table 2.87 Clinical Trial Details - Revumenib/Syndax Pharmaceuticals; Table 2.88 Clinical Trial Details - S64315/Servier; Table 2.89 Clinical Trial Details - S65487/Servier; Table 2.90 Clinical Trial Details - Sabatolimab/Novartis; Table 2.91 Clinical Trial Details - SAR443579/Sanofi; Table 2.92 Clinical Trial Details - SEL24/MEN1703/Menarini Group; Table 2.93 Clinical Trial Details - Siremadlin/Novartis; Table 2.94 Clinical Trial Details - Sorafenib/Bayer; Table 2.95 Clinical Trial Details - TAA05/PersonGen BioTherapeutics (Suzhou) Co., Ltd.; Table 2.96 Clinical Trial Details - Talazoparib/Pfizer; Table 2.97 Clinical Trial Details - Tamibarotene/Syros Pharmaceuticals; Table 2.98 Clinical Trial Details - TL-895/Telios Pharma, Inc.; Table 2.99 Clinical Trial Details - TTI-622/Pfizer; Table 2.100 Clinical Trial Details - VOR33/Vor Biopharma; Table 2.101 Clinical Trial Details - WU-NK-101/Wugen, Inc.; Table 2.102 Clinical Trial Details - Ziftomenib/Kura Oncology, Inc.; Table 2.103 Clinical Trial Details - ABBV-621 /AbbVie; Table 2.104 Clinical Trial Details - ABD-3001/Advanced BioDesign; Table 2.105 Clinical Trial Details - ADI-PEG 20/Polaris Group; Table 2.106 Clinical Trial Details - AMG 176/Amgen; Table 2.107 Clinical Trial Details - AMG 427/Amgen; Table 2.108 Clinical Trial Details - Anti-CD33 CAR NK Cells/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.; Table 2.109 Clinical Trial Details - APVO436/Aptevo Therapeutics; Table 2.110 Clinical Trial Details - Autologous CAR-T Cells/UTC Therapeutics Inc.; Table 2.111 Clinical Trial Details - AZD4573/AstraZeneca; Table 2.112 Clinical Trial Details - BMF-219/Biomea Fusion Inc.; Table 2.113 Clinical Trial Details - Bomedemstat/Imago BioSciences,Inc.; Table 2.114 Clinical Trial Details - BP1002/Bio-Path Holdings, Inc.; Table 2.115 Clinical Trial Details - BTX-1188/BioTheryX, Inc.; Table 2.116 Clinical Trial Details - BTX-A51/BioTheryX, Inc.; Table 2.117 Clinical Trial Details - CB-5339/Cleave Therapeutics, Inc.; Table 2.118 Clinical Trial Details - CC-90009/Bristol-Myers Squibb; Table 2.119 Clinical Trial Details - CC-90011/Bristol-Myers Squibb; Table 2.120 Clinical Trial Details - CC-91633/Bristol-Myers Squibb; Table 2.121 Clinical Trial Details - CC-95251/Bristol-Myers Squibb; Table 2.122 Clinical Trial Details - CC-96191/Bristol-Myers Squibb; Table 2.123 Clinical Trial Details - CD33xCD3 Bispecific Antibody/Y-mAbs Therapeutics; Table 2.124 Clinical Trial Details - Chidamide/Chipscreen Biosciences, Ltd.; Table 2.125 Clinical Trial Details - Clifutinib Besylate/Sunshine Lake Pharma Co., Ltd.; Table 2.126 Clinical Trial Details - CLN-049/Cullinan Oncology, LLC; Table 2.127 Clinical Trial Details - CYAD-02/Celyad Oncology SA; Table 2.128 Clinical Trial Details - CYNK-001/Celularity Incorporated; Table 2.129 Clinical Trial Details - DARIC33 (Pediatric)/2seventy bio; Table 2.130 Clinical Trial Details - Donafenib/Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Table 2.131 Clinical Trial Details - DS-1594 /Daiichi Sankyo Inc; Table 2.132 Clinical Trial Details - DSP107/Kahr Medical; Table 2.133 Clinical Trial Details - Entrectinib/Genentech, Inc.; Table 2.134 Clinical Trial Details - F16IL2/Philogen S.p.A.; Table 2.135 Clinical Trial Details - Fadraciclib/Cyclacel Pharmaceuticals, Inc; Table 2.136 Clinical Trial Details - FT516/Fate Therapeutics; Table 2.137 Clinical Trial Details - FT538/Fate Therapeutics; Table 2.138 Clinical Trial Details - Gentulizumab/GeneScience Pharmaceuticals Co., Ltd; Table 2.139 Clinical Trial Details - GNC-035/Sichuan Baili Pharmaceutical Co., Ltd; Table 2.140 Clinical Trial Details - GSK3745417/GlaxoSmithKline; Table 2.141 Clinical Trial Details - HMPL-306/Hutchison Medipharma Limited; Table 2.142 Clinical Trial Details - IGM-8444/IGM Biosciences, Inc.; Table 2.143 Clinical Trial Details - Imetelstat/Geron Corporation; Table 2.144 Clinical Trial Details - INB-100/In8bio Inc.; Table 2.145 Clinical Trial Details - IO-202/Immune-Onc Therapeutics; Table 2.146 Clinical Trial Details - JNJ-63709178/Janssen Research & Development, LLC; Table 2.147 Clinical Trial Details - JNJ-67571244/Janssen Research & Development, LLC; Table 2.148 Clinical Trial Details - JNJ-74856665/Janssen Research & Development, LLC; Table 2.149 Clinical Trial Details - KITE-222/Kite Pharma; Table 2.150 Clinical Trial Details - KPT-9274/Karyopharm Therapeutics Inc; Table 2.151 Clinical Trial Details - LNK01002/Lynk Pharmaceuticals Co., Ltd; Table 2.152 Clinical Trial Details - LP-108/Newave Pharmaceutical Inc; Table 2.153 Clinical Trial Details - LP-118/Newave Pharmaceutical Inc; Table 2.154 Clinical Trial Details - Luxeptinib/Aptose Biosciences Inc.; Table 2.155 Clinical Trial Details - LY3214996/Eli Lilly and Company; Table 2.156 Clinical Trial Details - LY3410738/Loxo Oncology, Inc.; Table 2.157 Clinical Trial Details - Mana 312/Mana Therapeutics; Table 2.158 Clinical Trial Details - MB-102/Mustang Bio, Inc.; Table 2.159 Clinical Trial Details - MCLA-117/Merus N.V.; Table 2.160 Clinical Trial Details - MGTA-117/Magenta Therapeutics, Inc.; Table 2.161 Clinical Trial Details - Minnelide/Minneamrita Therapeutics LLC; Table 2.162 Clinical Trial Details - MK-0482/Merck Sharp & Dohme LLC; Table 2.163 Clinical Trial Details - MRX-2843/Xcovery Holdings, Inc; Table 2.164 Clinical Trial Details - Navitoclax/AbbVie; Table 2.165 Clinical Trial Details - NEI-01/New Epsilon Innovation Limited; Table 2.166 Clinical Trial Details - Nintedanib/Boehringer Ingelheim; Table 2.167 Clinical Trial Details - NKX101/Nkarta Inc.; Table 2.168 Clinical Trial Details - NTX 301/Pinotbio; Table 2.169 Clinical Trial Details - OPB-111077/Otsuka America Pharmaceutical; Table 2.170 Clinical Trial Details - PDR001/Novartis; Table 2.171 Clinical Trial Details - Pemigatinib/Incyte Corporation; Table 2.172 Clinical Trial Details - PHI-101/Pharos iBio Co., Ltd.; Table 2.173 Clinical Trial Details - PRGN-3006/Precigen, Inc; Table 2.174 Clinical Trial Details - PRT1419/Prelude Therapeutics; Table 2.175 Clinical Trial Details - PRT543/Prelude Therapeutics; Table 2.176 Clinical Trial Details - Pyronaridine Tetraphosphate/Armaceutica, Inc; Table 2.177 Clinical Trial Details - RC1012/Guangdong Ruishun Biotech Co., Ltd; Table 2.178 Clinical Trial Details - Regorafenib/Bayer; Table 2.179 Clinical Trial Details - RO7283420/Hoffmann-La Roche; Table 2.180 Clinical Trial Details - RVT-2001/Hemavant Sciences GmbH; Table 2.181 Clinical Trial Details - RVU120/Ryvu Therapeutics SA; Table 2.182 Clinical Trial Details - SEA-CD70/Seagen Inc.; Table 2.183 Clinical Trial Details - Selinexor/Karyopharm Therapeutics Inc; Table 2.184 Clinical Trial Details - SH1573/Nanjing Sanhome Pharmaceutical, Co., Ltd.; Table 2.185 Clinical Trial Details - SHR-1702/Jiangsu HengRui Medicine Co., Ltd.; Table 2.186 Clinical Trial Details - SKI-G-801/Oscotec Inc.; Table 2.187 Clinical Trial Details - SL-172154 + Azacitidine +/- Venetoclax/Shattuck Labs, Inc.; Table 2.188 Clinical Trial Details - SL-401/Stemline Therapeutics, Inc.; Table 2.189 Clinical Trial Details - SY-2101/Syros Pharmaceuticals; Table 2.190 Clinical Trial Details - TAS1440/Astex Pharmaceuticals, Inc.